Towards Translation of PqsR Inverse Agonists: From In Vitro Efficacy Optimization to In Vivo Proof‐of‐Principle (Adv. Sci. 5/2023)

Quorum Sensing Inhibitor In article number 2204443, Martin Empting and colleagues describe the medicinal‐chemistry‐driven discovery of a new quorum sensing inhibitor (QSI) against Pseudomonas aeruginosa. The discovered QSI synergized with standard‐of‐care antibiotic tobramycin in a murine infection...

Descripción completa

Detalles Bibliográficos
Autores principales: Hamed, Mostafa M., Abdelsamie, Ahmed S., Rox, Katharina, Schütz, Christian, Kany, Andreas M., Röhrig, Teresa, Schmelz, Stefan, Blankenfeldt, Wulf, Arce‐Rodriguez, Alejandro, Borrero‐de Acuña, José Manuel, Jahn, Dieter, Rademacher, Jessica, Ringshausen, Felix C., Cramer, Nina, Tümmler, Burkhard, Hirsch, Anna K. H., Hartmann, Rolf W., Empting, Martin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Frontispiece
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9929108/
http://dx.doi.org/10.1002/advs.202370027
Descripción
Sumario:Quorum Sensing Inhibitor In article number 2204443, Martin Empting and colleagues describe the medicinal‐chemistry‐driven discovery of a new quorum sensing inhibitor (QSI) against Pseudomonas aeruginosa. The discovered QSI synergized with standard‐of‐care antibiotic tobramycin in a murine infection model providing an in vivo proof‐of‐concept. [Image: see text]

Ejemplares similares